http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
특발성 간질성 폐렴 환자에서 Matrix Metalloproteinase-1과 Tissue Inhibitor of Metalloproteinase-1, -2의 면역조직화학적 연구
경선영 ( Gyeong Seon Yeong ),임영희 ( Im Yeong Hui ),안창혁 ( An Chang Hyeog ),박정웅 ( Park Jeong Ung ),정성환 ( Jeong Seong Hwan ),신익균 ( Sin Ig Gyun ),하승연 ( Ha Seung Yeon ),이재웅 ( Lee Jae Ung ) 대한내과학회 2003 대한내과학회지 Vol.65 No.2
Background : In the idiopathic interstitial pneumonia (IIP), it has been known that imbalance between matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) is important factor for abnormal remodeling of lung parenchyme. This
특발성 간질성 폐렴 환자에서 임상적 지표와 혈청 Angiotensin Converting Enzyme(ACE) 및 Angiotensin 2와의 관계
경선영 ( Gyeong Seon Yeong ),한혜숙 ( Han Hye Sug ),송석호 ( Song Seog Ho ),황준규 ( Hwang Jun Gyu ),임영희 ( Im Yeong Hui ),안창혁 ( An Chang Hyeog ),박계영 ( Park Gye Yeong ),박정웅 ( Park Jeong Ung ),정성환 ( Jeong Seong Hwa 대한결핵 및 호흡기학회 2002 Tuberculosis and Respiratory Diseases Vol.52 No.5
특발성 폐섬유화증 환자의 치료에서 Angiotensin 2 Receptor Antagonist의 치료효과
우덕수 ( U Deog Su ),설원종 ( Seol Won Jong ),경선영 ( Gyeong Seon Yeong ),임영희 ( Im Yeong Hui ),안창혁 ( An Chang Hyeog ),박정웅 ( Park Jeong Ung ),정성환 ( Jeong Seong Hwan ),이재웅 ( Lee Jae Ung ) 대한결핵 및 호흡기학회 2003 Tuberculosis and Respiratory Diseases Vol.55 No.5
확장기 소세포 폐암에서 Carboplatin, Ifosfamide, Etoposide 복합화학요법의 효과
류희정 ( Hee Juang Ryu ),김영남 ( Young Nam Kim ),경선영 ( Seon Yeong Gyeong ),박세훈 ( Se Hoon Park ),안창혁 ( Chang Hyeok An ),방수미 ( Soo Mee Bang ),이상표 ( Sang Pyo Lee ),이재익 ( Jae Ik Lee ),박정웅 ( Jeong Ung Park ),조은 대한내과학회 2006 대한내과학회지 Vol.70 No.6
Background: This prospective phase II study assessed the efficacy and toxicity of the combination of carboplatin, ifosfamide and etoposide for previously untreated patients with extensive-disease small cell lung cancer (ED-SCLC). Methods: Patients with ED-SCLC received a combination chemotherapy with carboplatin AUC 6.0 on day 1, ifosfamide 1200 mg/m2 on day 1-3, and etoposide 100 mg/m2 on day 1-3. Results: Forty-one patients received a median of six cycles of chemotherapy. A complete response was seen in 5 patients and a partial response was seen in 33 patients (overall response 95%). The median duration of the response was 5.1 months (95% CI; 3.4-6.8 months). The median time to progression and overall survival were 7.4 months (95% CI; 6.1-8.6 months) and 10.7 months (95% CI; 6.9-14.6 months), respectively, providing the one-year survival rate of 43.9%. Grade 3~4 anemia, neutropenia and thrombocytopenia occurred in 14%, 7% and 6% in a total of 212 cycles, respectively. Non-hematologic toxicities were generally mild and manageable. No treatment related death was observed. Conclusions: The combination chemotherapy of carboplatin, etoposide and ifosfamide showed an effective response rate and acceptable toxicity.(Korean J Med 70:688-694, 2006)